GlassScriptPhysician profile
Sheryl A Cowan
NPI 1164430302
$4,677.26
in general payments reported to CMS, 2019-2025
44 companies · $593 in 2025
The $593 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $760 · 2021: $766 · 2022: $563 · 2023: $545 · 2024: $575 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,154.72 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $433.32 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $359.97 | 2019-2023 | Spravato, Xarelto |
| Abbvie INC. | $338.72 | 2019-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $270.33 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $229.97 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Lilly USA, LLC | $201.59 | 2021-2025 | Jardiance, Emgality, Zepbound |
| Genentech USA, INC. | $159.59 | 2019-2022 | |
| Novo Nordisk INC | $145.12 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $140.98 | 2023-2025 | |
| Sanofi Pasteur INC. | $107.51 | 2019-2025 | |
| Validus Pharmaceuticals LLC | $95.96 | 2025 | Raldesy, Lopressor |
| Allergan, INC. | $87.60 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $76.02 | 2021 | |
| Amarin Pharma, INC. | $68.44 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheryl Cowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.